Paper859634
High-LET radiations induce a large proportion of non-rejoining DNA breaks.
Ritter MA and 2 others. Nature, 1977. Cited by 330 papers, by iCite.
Cite this record
ConductScience Library. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Papers, record 859634. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/859634
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Survival | Major topic |
| DNA | Major topic |
| Energy Transfer | Major topic |
| Radiation, Ionizing | Major topic |
| Cell Line | |
| Dose-Response Relationship, Radiation | |
| X-Rays |
Source PubMed
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 330 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42883456 | Bone Radiopharmaceuticals: Evolution from Palliative Therapy to Targeted Precision Oncology and Theranostics. | Biology (Basel) | 2026 | https://conductscience.org/library/papers/42883456 | PubMed |
| 42569093 | Real-World Outcomes of Combination Therapy With Radium-223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer. | Adv Urol | 2026 | https://conductscience.org/library/papers/42569093 | PubMed |
| 41145955 | In silico assessment of cellular damage from Lu-177, Ac-225, and Pb-212 therapeutic radionuclides. | Med Phys | 2025 | https://conductscience.org/library/papers/41145955 | PubMed |
| 39622964 | The effects of cell displacement on DNA damages in targeted radiation therapy using Geant4-DNA. | Sci Rep | 2024 | https://conductscience.org/library/papers/39622964 | PubMed |
| 38921049 | Simulation of Radiation-Induced DNA Damage and Protection by Histones Using the Code RITRACKS. | BioTech (Basel) | 2024 | https://conductscience.org/library/papers/38921049 | PubMed |
| 38481668 | Combining theranostic/particle therapy with immunotherapy for the treatment of GU malignancies. | BJUI Compass | 2024 | https://conductscience.org/library/papers/38481668 | PubMed |
| 37894414 | Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37894414 | PubMed |
| 36012698 | Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36012698 | PubMed |
| 35657158 | Genomic biomarkers to guide precision radiotherapy in prostate cancer. | Prostate | 2022 | https://conductscience.org/library/papers/35657158 | PubMed |
| 34084750 | Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. | Front Oncol | 2021 | https://conductscience.org/library/papers/34084750 | PubMed |
| 34039648 | Radium-223-Induced Bystander Effects Cause DNA Damage and Apoptosis in Disseminated Tumor Cells in Bone Marrow. | Mol Cancer Res | 2021 | https://conductscience.org/library/papers/34039648 | PubMed |
| 33882773 | Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice. | Int J Hyperthermia | 2021 | https://conductscience.org/library/papers/33882773 | PubMed |
| 33558017 | Alpha emitting nuclides for targeted therapy. | Nucl Med Biol | 2021 | https://conductscience.org/library/papers/33558017 | PubMed |
| 33142739 | The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33142739 | PubMed |
| 31712765 | Radium-223 mechanism of action: implications for use in treatment combinations. | Nat Rev Urol | 2019 | https://conductscience.org/library/papers/31712765 | PubMed |
| 30775252 | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. | Asian J Urol | 2019 | https://conductscience.org/library/papers/30775252 | PubMed |
| 30293905 | Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects. | Eur Urol | 2019 | https://conductscience.org/library/papers/30293905 | PubMed |
| 29977175 | The Lowest Radiation Dose Having Molecular Changes in the Living Body. | Dose Response | 2018 | https://conductscience.org/library/papers/29977175 | PubMed |
| 29800455 | Estimation of the radiation-induced DNA double-strand breaks number by considering cell cycle and absorbed dose per cell nucleus. | J Radiat Res | 2018 | https://conductscience.org/library/papers/29800455 | PubMed |
| 28919714 | Radium 223 dichloride for prostate cancer treatment. | Drug Des Devel Ther | 2017 | https://conductscience.org/library/papers/28919714 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/859634
GET https://conductscience.org/api/papers/v1/859634/cited_by?page=2